Project Grant F30CA290958
Award Date
8/1/25
Completion Date
Not listed
Dollars Obligated
$109K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
West Virginia, USA
Similar Awards
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant to The Johns Hopkins University to conduct research on comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The project, funded under CFDA 93.398 Cancer Research Manpower, aims to characterize differences in tumor-associated macrophage (TAM) functional attributes and their regulation between M-CSF and GM-CSF, as well as investigate...
This $1,130,538 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to target the tumor-specific Tn antigen in pancreatic ductal adenocarcinoma (PDAC). The University of Louisville, as the prime awardee, will: Determine how the Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins using mouse models and clinical specimens. Validate the role of natural killer cells in the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,835 to Cambium Oncology LLC to develop a novel "armored" CAR-T immunotherapeutic for the treatment of pancreatic ductal adenocarcinoma (PDAC). The project aims to engineer CAR-T cells that target the MUC16 antigen on PDAC cells and secrete a VIP receptor antagonist to disrupt the immunosuppressive tumor microenvironment. The two-phase project will first validate the VIP...
The National Cancer Institute (NCI) awarded Case Western Reserve University (CWRU) a 5-year, $654,681 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative anticancer nanovaccines for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this grant include: Designing and developing multifunctional ionizable lipid nanoparticle (ELNP) based peptide vaccines for effective PDAC...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development and evaluation of a novel Chimeric Antigen Receptor Macrophage (CAR-M) therapy targeting triple-negative breast cancer (TNBC). The $218,089 award to the University of California, Santa Barbara aims to enhance the tumor-infiltrating and phagocytic capabilities of anti-CSPG4 CAR-Ms through the co-expression of an active form of the Rac2 protein. This approach, known as...
The U.S. National Cancer Institute (NCI) awarded a $626,534 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Medical University of South Carolina (MUSC) to support a 5-year research project titled "Dissecting the Mechanism for Transient ER Stress-Induced Anti-Tumor T Cell Response." The project aims to investigate how transient endoplasmic reticulum (ER) stress can improve the function and anti-tumor efficacy of T cells, particularly through modulating mitochondrial...
The National Institutes of Health's National Cancer Institute awarded a $283,136 Project Grant to the Regents of the University of Michigan under the Cancer Research Manpower federal grant program (CFDA 93.398). The award will support research investigating cellular communication in the tumor microenvironment of pancreatic cancer. The grantee will examine how hedgehog signaling alters the immune landscape and endothelial cell function through fibroblast interactions. They will also determine the...
This $139,445 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will fund research by the Regents of the University of Michigan to characterize the role of mesothelial-derived cancer-associated fibroblasts (CAFs) in the pathogenesis of pancreatic ductal adenocarcinoma (PDA). The central hypothesis is that mesothelial cells give rise to a distinct, immunomodulatory population of CAFs that influence the PDA tumor microenvironment. Through in...
This $642,755 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding research by The Institute for Cancer Research to investigate the role of the protein Anoctamin 6 (ANO6) in enabling cancer-associated fibroblasts (CAFs) to transfer lipids to pancreatic ductal adenocarcinoma (PDAC) tumor cells through a process called trogocytosis. The study aims to determine how ANO6 activity is regulated in the CAF-cancer cell interface, understand how...